| scholarly article | Q13442814 |
| P50 | author | Holger Moch | Q90210393 |
| Tullio Sulser | Q92006035 | ||
| P2093 | author name string | Wilhelm Krek | |
| Peter Schraml | |||
| Rafal Pawłowski | |||
| Sarah M Mühl | |||
| P2860 | cites work | S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling | Q24297650 |
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 | ||
| Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study | Q24813050 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Q29615757 | ||
| Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer | Q33520392 | ||
| Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer | Q33865946 | ||
| Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence | Q34069831 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. | Q34530199 | ||
| Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. | Q34569182 | ||
| Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. | Q34881288 | ||
| Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers | Q34935968 | ||
| Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma | Q35807817 | ||
| pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation | Q36731316 | ||
| Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. | Q36748085 | ||
| VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy | Q37393004 | ||
| Alterations in VHL as potential biomarkers in renal-cell carcinoma | Q37724576 | ||
| Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 | ||
| Prognostic and predictive biomarkers in renal cell carcinoma | Q37768078 | ||
| Kidney cancer pathology in the new context of targeted therapy | Q37890209 | ||
| VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations | Q39515837 | ||
| VHL loss causes spindle misorientation and chromosome instability. | Q39822734 | ||
| Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up | Q40048716 | ||
| pVHL and GSK3beta are components of a primary cilium-maintenance signalling network | Q40142798 | ||
| Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 | ||
| Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. | Q45880509 | ||
| Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. | Q52856655 | ||
| pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. | Q54551413 | ||
| Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer | Q57693466 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | E11-7 | |
| P577 | publication date | 2012-10-03 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Loss of PBRM1 expression is associated with renal cell carcinoma progression | |
| P478 | volume | 132 |
| Q41187419 | A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization |
| Q26849467 | ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy |
| Q38545726 | BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies |
| Q41050010 | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
| Q38379487 | Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation |
| Q38986014 | Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes |
| Q38184386 | Biomarkers in renal cancer |
| Q90711847 | Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma |
| Q28073283 | Choosing the right cell line for renal cell cancer research |
| Q37573538 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. |
| Q36693136 | Clinical significance of in vivo cytarabine-induced gene expression signature in AML. |
| Q33583093 | Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC. |
| Q37627446 | Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. |
| Q35640108 | Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma |
| Q38639828 | Driver mutations of cancer epigenomes. |
| Q28079377 | Epigenetic determinants of metastasis |
| Q90376039 | Epigenetic modifiers: activities in renal cell carcinoma |
| Q41574276 | Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma |
| Q38676794 | Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma |
| Q61815553 | Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma |
| Q42768997 | Expression of Von Hippel - Lindau (VHL) gene mutation in diagnosed cases of renal cell carcinoma. |
| Q41703426 | Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours |
| Q26785930 | Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms |
| Q48307020 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma |
| Q27025984 | Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma |
| Q37414110 | Histone modifications: implications in renal cell carcinoma |
| Q90643323 | Hypermethylation of BRM promoter plays oncogenic roles in development of clear cell renal cell carcinoma |
| Q39821089 | Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit |
| Q64084325 | Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1 |
| Q33913967 | Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma |
| Q93182714 | Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma |
| Q51101527 | Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma. |
| Q34758616 | Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma |
| Q36095258 | Low PBRM1 identifies tumor progression and poor prognosis in breast cancer |
| Q48098684 | Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. |
| Q58693750 | Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma |
| Q33710257 | Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy |
| Q38264616 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art |
| Q38910995 | Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact |
| Q93379768 | Mutations in renal cell carcinoma |
| Q92854022 | New Insights into the Role of Polybromo-1 in Prostate Cancer |
| Q38294198 | New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours. |
| Q38852640 | PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas |
| Q35995926 | PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma |
| Q38122565 | PBRM1 and BAP1 as novel targets for renal cell carcinoma |
| Q47370222 | PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival |
| Q41532653 | PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway |
| Q53089460 | Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. |
| Q38970282 | Precision medicine from the renal cancer genome |
| Q92154621 | Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma |
| Q50050542 | Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. |
| Q38794945 | Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens |
| Q38170411 | Protein kinase inhibitors in renal cell carcinoma. |
| Q57178229 | Renal Cell Carcinoma: Molecular Aspects |
| Q26860500 | Renal tumors: diagnostic and prognostic biomarkers |
| Q41883228 | Somatic mutaome profile in human cancer tissues |
| Q26746038 | Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy |
| Q93102798 | The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma |
| Q51091490 | The epigenetic landscape of clear-cell renal cell carcinoma. |
| Q39021700 | The epigenetic landscape of renal cancer |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q38811459 | The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma |
| Q28083152 | The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer |
| Q37484160 | Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project |
| Q37705808 | VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma |
| Q87422849 | [Renal cancer biomarkers. What is justified?] |
Search more.